Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2013 1
2015 2
2016 1
2017 2
2018 1
2019 1
2020 1
2022 1
2023 1
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

10 results

Results by year

Citations

1 article found by citation matching

Search results

Filters applied: . Clear all
Page 1
Predictive markers of safety and immunogenicity of adjuvanted vaccines.
Mastelic B, Garçon N, Del Giudice G, Golding H, Gruber M, Neels P, Fritzell B. Mastelic B, et al. Biologicals. 2013 Nov;41(6):458-68. doi: 10.1016/j.biologicals.2013.08.006. Epub 2013 Sep 23. Biologicals. 2013. PMID: 24071553
Vaccination represents one of the greatest public health triumphs; in part due to the effect of adjuvants that have been included in vaccine preparations to boost the immune responses through different mechanisms. ...This report reflects the conclusions of a …
Vaccination represents one of the greatest public health triumphs; in part due to the effect of adjuvants that have been inclu …
Prediction of long-term kinetics of vaccine-elicited neutralizing antibody and time-varying vaccine-specific efficacy against the SARS-CoV-2 Delta variant by clinical endpoint.
Chen X, Wang W, Chen X, Wu Q, Sun R, Ge S, Zheng N, Lu W, Yang J, Rodewald L, Yu H. Chen X, et al. BMC Med. 2022 Jan 28;20(1):36. doi: 10.1186/s12916-022-02249-9. BMC Med. 2022. PMID: 35086547 Free PMC article.
METHODS: We used a previously published model and neutralization data for five vaccines-mRNA-1273, BNT162b2, NVX-CoV2373, V01, and CoronaVac- to evaluate long-term neutralizing antibody dynamics and predict time-varying efficacy against the Delta variant by specific …
METHODS: We used a previously published model and neutralization data for five vaccines-mRNA-1273, BNT162b2, NVX-CoV2373, V01, and Co …
Beyond CTLA-4: novel immunotherapy strategies for metastatic melanoma.
Matikas A, Mavroudis D. Matikas A, et al. Future Oncol. 2015;11(6):997-1009. doi: 10.2217/fon.14.287. Future Oncol. 2015. PMID: 25760979 Review.
Unfortunately, although response rates are high, disease progression is universal. Despite the success of IL-2 and adjuvant IFL-alpha2b, these two agents remained the only approved immunotherapy approaches. ...However, the potential adverse events, the optimal use of these …
Unfortunately, although response rates are high, disease progression is universal. Despite the success of IL-2 and adjuvant IFL-alpha …
Immunotherapies in Early and Advanced Renal Cell Cancer.
Kasenda B, Larkin J, Gore M. Kasenda B, et al. Prog Tumor Res. 2015;42:1-10. doi: 10.1159/000436988. Epub 2015 Sep 4. Prog Tumor Res. 2015. PMID: 26376844 Review.
Vaccines have continued to be investigated in advanced and adjuvant settings. No trial has so far established vaccines as a standard treatment in either situation. ...We will also touch briefly on the adjuvant situation and tumour vaccines....
Vaccines have continued to be investigated in advanced and adjuvant settings. No trial has so far established vaccines …
A library of recombinant Babesia microti cell surface and secreted proteins for diagnostics discovery and reverse vaccinology.
Elton CM, Rodriguez M, Ben Mamoun C, Lobo CA, Wright GJ. Elton CM, et al. Int J Parasitol. 2019 Feb;49(2):115-125. doi: 10.1016/j.ijpara.2018.10.003. Epub 2018 Oct 24. Int J Parasitol. 2019. PMID: 30367868 Free PMC article.
The recent sequencing of the B. microti genome has revealed many novel genes encoding proteins that can now be tested for their suitability as subunit vaccine candidates and diagnostic serological markers. Extracellular proteins are considered excellent vaccine …
The recent sequencing of the B. microti genome has revealed many novel genes encoding proteins that can now be tested for their suitability …
Topical Imiquimod Plus Nab-paclitaxel for Breast Cancer Cutaneous Metastases: A Phase 2 Clinical Trial.
Salazar LG, Lu H, Reichow JL, Childs JS, Coveler AL, Higgins DM, Waisman J, Allison KH, Dang Y, Disis ML. Salazar LG, et al. JAMA Oncol. 2017 Jul 1;3(7):969-973. doi: 10.1001/jamaoncol.2016.6007. JAMA Oncol. 2017. PMID: 28114604 Free PMC article. Clinical Trial.
MAIN OUTCOMES AND MEASURES: The primary endpoint was safety and ORR. Secondary endpoints included the generation of tumor-infiltrating lymphocytes and modulation of immune cell populations. ...Preexisting levels of cells indicating either T-cell exhaustion or systemic immu …
MAIN OUTCOMES AND MEASURES: The primary endpoint was safety and ORR. Secondary endpoints included the generation of tumor-infiltratin …
Blood immune cells as potential biomarkers predicting relapse-free survival of stage III/IV resected melanoma patients treated with peptide-based vaccination and interferon-alpha.
Moschella F, Buccione C, Ruspantini I, Castiello L, Rozo Gonzalez A, Iacobone F, Ferraresi V, Palermo B, Nisticò P, Belardelli F, Proietti E, Macchia I, Urbani F. Moschella F, et al. Front Oncol. 2023 May 18;13:1145667. doi: 10.3389/fonc.2023.1145667. eCollection 2023. Front Oncol. 2023. PMID: 37274275 Free PMC article.
We previously demonstrated safety, immunogenicity and preliminary evidence of clinical efficacy in stage III/IV resected melanoma patients subjected to a combination therapy based on peptide vaccination together with intermittent low-dose interferon-alpha2b, …
We previously demonstrated safety, immunogenicity and preliminary evidence of clinical efficacy in stage III/IV resected melan …
A phase I study of multi-HLA-binding peptides derived from heat shock protein 70/glypican-3 and a novel combination adjuvant of hLAG-3Ig and Poly-ICLC for patients with metastatic gastrointestinal cancers: YNP01 trial.
Nakajima M, Hazama S, Tamada K, Udaka K, Kouki Y, Uematsu T, Arima H, Saito A, Doi S, Matsui H, Shindo Y, Matsukuma S, Kanekiyo S, Tokumitsu Y, Tomochika S, Iida M, Yoshida S, Nakagami Y, Suzuki N, Takeda S, Yamamoto S, Yoshino S, Ueno T, Nagano H. Nakajima M, et al. Cancer Immunol Immunother. 2020 Aug;69(8):1651-1662. doi: 10.1007/s00262-020-02518-7. Epub 2020 Mar 26. Cancer Immunol Immunother. 2020. PMID: 32219501 Free PMC article. Clinical Trial.
BACKGROUND: This phase I study aimed to evaluate the safety, peptide-specific immune responses, and anti-tumor effects of a novel vaccination therapy comprising multi-HLA-binding heat shock protein (HSP) 70/glypican-3 (GPC3) peptides and a novel adjuvant comb …
BACKGROUND: This phase I study aimed to evaluate the safety, peptide-specific immune responses, and anti-tumor effects of a novel …
Clinical trials with allergen products: in search of biological markers of efficacy.
Moingeon P. Moingeon P. Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M. 2006;(95):182-7; discussion 187-8. Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M. 2006. PMID: 17393738
I discuss herein our efforts to identify biological markers of efficacy in support of the development of sublingual allergy vaccines. Biomarkers are of major interest to facilitate clinical development, for example by predicting safety and efficacy of …
I discuss herein our efforts to identify biological markers of efficacy in support of the development of sublingual allergy vaccin …
Phase II clinical trial using novel peptide cocktail vaccine as a postoperative adjuvant treatment for surgically resected pancreatic cancer patients.
Miyazawa M, Katsuda M, Maguchi H, Katanuma A, Ishii H, Ozaka M, Yamao K, Imaoka H, Kawai M, Hirono S, Okada KI, Yamaue H. Miyazawa M, et al. Int J Cancer. 2017 Feb 15;140(4):973-982. doi: 10.1002/ijc.30510. Epub 2016 Nov 21. Int J Cancer. 2017. PMID: 27861852 Clinical Trial.
We investigated peptide cocktail vaccine OCV-C01 containing epitope peptides derived from KIF20A, vascular endothelial growth factor receptor (VEGFR)1 and VEGFR2 combined with gemcitabine in the adjuvant treatment for resected pancreatic cancer patients. ...The prim …
We investigated peptide cocktail vaccine OCV-C01 containing epitope peptides derived from KIF20A, vascular endothelial growth factor …